Health
“Levothyroxine is one of the top 5 most prescribed drugs in the U.S." (headline claim, presented within a post whose surrounding text asserts: levothyroxine "can cause heart palpitations, bone loss, and nutrient depletion (selenium, zinc, iron, B12, iodine)"; "the odds of your doctor ever taking you off are slim"; "Studies show that…”
Plain restatementLevothyroxine ranks among the five most frequently dispensed prescription medications in the United States.
General information only - not medical advice.
The headline statistic in this post is correct. Levothyroxine really is one of the five most prescribed drugs in the United States, ranking around third with roughly 81 million prescriptions a year. But that number mostly reflects how common thyroid disease is and the fact that a daily medication gets refilled several times a year, about four prescriptions per patient annually. It is not evidence of overprescribing. The post's other claims are weaker. The idea that the drug depletes iron, B12, zinc and selenium reverses the actual pharmacology, since those minerals interfere with absorbing the drug rather than the other way around. Palpitations and bone loss are linked to taking too much thyroid hormone, not to a correctly adjusted dose. The claim that ashwagandha works "without the side effects" is contradicted by published reports of liver injury and dangerously high thyroid hormone levels, and the human evidence is one small eight-week trial in people with mild thyroid abnormalities only, with no trials at all in full hypothyroidism. Some people on low doses can be tapered off under medical supervision, which is an active research topic in mainstream endocrinology, but that does not apply to people whose thyroid has genuinely failed or been removed. Anyone considering changing a thyroid dose should do so with their prescriber and lab monitoring rather than on their own.
Levothyroxine [drifted from the evidence:] is one of the [drifted from the evidence:] top 5 most [drifted from the evidence:] prescribed drugs in the [drifted from the evidence:] U.S." (headline claim, presented within a post whose surrounding text asserts: levothyroxine "can cause heart palpitations, bone loss, and nutrient depletion (selenium, zinc, iron, B12, iodine)"; "the odds of your doctor ever taking you off are slim"; "Studies show that natural support like ashwagandha + selenium can help improve thyroid function (without the side effects)"; "You don't have to rely on a thyroid medication for the rest of your life.")
Levothyroxine [added by the neutral restatement:] ranks among the [added by the neutral restatement:] five most [added by the neutral restatement:] frequently dispensed prescription medications in the [added by the neutral restatement:] United States.
Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.
The trace / claim to source
- Levothyroxine is one of the top 5 most prescribed drugs in the U.S. This is correct across every independent dataset checked, with recent ranks of #2 to #4. The headline claim is accurate as stated.
- Levothyroxine is frequently continued indefinitely, and a meaningful minority of selected patients could stop it. The JAMA data showing 25.7% overall and 64% at doses of 50 µg/day or lower, and the meta-analytic 37% remaining euthyroid, support the narrower point that reflexive lifelong continuation is sometimes unexamined.
- Subclinical hypothyroidism is frequently self-limiting, with 61% spontaneously reverting to euthyroidism, and treating it has not shown benefit in high-certainty evidence.
- Heart palpitations and bone loss are real risks of excess thyroid hormone exposure, documented in the TSH-suppression literature.
- Selenium has some evidence in Hashimoto's thyroiditis, including possible antibody reduction and possible levothyroxine dose reduction.
- Some patients do report persistent symptoms despite biochemically normal results. This is a recognized clinical problem, not an invention.
- Marketing as evidence / statistic repurposed as indictment. The "top 5" figure is true but functions in the post as implied proof of overprescribing. Prescription volume reflects disease prevalence, chronic daily dosing, and refill frequency. The same dataset shows roughly 4.4 prescriptions per patient per year. High rank is not evidence of inappropriate use.
- Reversed causal direction (fabricated mechanism). "These meds can deplete your body of key nutrients like selenium, zinc, iron, and B12" inverts the documented pharmacology. Iron, calcium, and magnesium impair levothyroxine absorption; levothyroxine does not deplete them. No credible source for drug-induced depletion of these nutrients was located.
- Omitted qualifier on harms. Palpitations and bone loss are associated with overtreatment and TSH suppression, not with appropriately dosed replacement. Presenting them as inherent properties of "thyroid medication" removes the dose-dependency that is the entire point, and omits that fracture findings are inconsistent across cohorts.
- Subgroup generalization. "You don't have to rely on a thyroid medication for the rest of your life" extrapolates from older adults on 50 µg/day or less with largely subclinical disease to all viewers, including people with overt hypothyroidism, Hashimoto's with established failure, thyroidectomy, or radioactive-iodine ablation, for whom replacement is non-optional.
- Exaggeration from a pilot trial. "Studies show" rests on one 8-week, 50-person pilot trial in subclinical hypothyroidism with biochemical surrogate endpoints. There are no trials in overt hypothyroidism.
- Directly contradicted safety claim. "(without the side effects)" is refuted by the evidence. Ashwagandha has documented case reports of thyrotoxicosis, acute liver injury including in healthy young adults, and reported endocrine disruption and adrenal suppression. Describing it as side-effect-free is false.
- Care substitution framing. The combination of "reducing your dependence on medication," an unverified causal harm mechanism, and a monetized class creates pressure to reduce or stop a prescribed hormone. The literature includes a case report of a patient who replaced levothyroxine with ashwagandha. Untreated or undertreated hypothyroidism carries real consequences, and dose changes require biochemical monitoring by a clinician.
- "What most doctors don't tell you." Deprescribing is an active, published area of mainstream endocrinology, appearing in JAMA. The framing of suppressed knowledge is contradicted by the very literature that supports the post's strongest point.
- Exact current-year rank for 2025 or 2026 could not be established. Available data runs through 2023 (ClinCalc) and 2025 claims-share estimates. This does not affect the verdict, since the claim is a top-5 band.
- Effect sizes and confidence intervals from the ashwagandha pilot trial were not retrievable from accessed sources, only direction of effect and significance.
- The prevalence of persistent symptoms despite normal labs is a recognized phenomenon, but no primary quantification was retrieved in this investigation, so the post's "countless patients" cannot be sized.
- Whether selenium supplementation improves patient-relevant outcomes, as opposed to antibody titres and dose requirements, remains unsettled; the Cochrane review characterized the evidence base as limited.
- Iodine was named in the post's depletion list but no evidence either way was located for a levothyroxine-iodine depletion effect.
On the headline statistic: ClinCalc's DrugStats database records levothyroxine's top drug rank as #3 with an estimated 80,930,390 prescriptions in the United States in 2023. Its rank over time was #2 in 2019, #2 in 2020, #3 in 2021, #4 in 2022, and #3 in 2023. Independent rankings agree on the same band: a GoodRx-derived list places levothyroxine 3rd behind atorvastatin and amlodipine, and 2025 Definitive Healthcare data lists levothyroxine sodium third at 1.83% of claims, behind atorvastatin at 2.74% and amlodipine at 1.86%. The drug has sat between #2 and #4 for roughly a decade. The headline statistic is correct. On discontinuation: the post's framing is partially supported and partially contradicted by the same body of evidence. A JAMA editorial notes that levothyroxine is widely prescribed and often continued lifelong despite 61% of patients with subclinical hypothyroidism spontaneously reverting to euthyroidism, and high-certainty evidence failing to demonstrate benefit from treating subclinical hypothyroidism. In the prospective JAMA study, among 370 participants with a median baseline dose of 50 µg/day, 95 (25.7%) successfully stopped levothyroxine, and among the 88 participants taking 50 µg/day or lower, 56 (64%) successfully discontinued. A systematic review and meta-analysis of 17 observational studies (N=1103) found 37% of patients remained euthyroid after thyroid hormone discontinuation, with a higher proportion remaining euthyroid among those with an initial diagnosis of subclinical hypothyroidism than among those with overt hypothyroidism. Critically, this is low-certainty evidence confined to selected patients on low doses, not a general property of thyroid medication. On ashwagandha: human evidence is a single small pilot trial. A randomized, double-blind, placebo-controlled pilot study included 50 patients with subclinical hypothyroidism (elevated TSH but normal T3 and T4); subjects aged 18 to 50 with TSH of 4.5 to 10 mIU/L received 300 mg of ashwagandha root extract or placebo twice daily for 8 weeks, with T3 and T4 increasing significantly over placebo at weeks 4 and 8. However, efficacy in treating hypothyroidism remains unclear due to potential supplement contamination and a lack of clinical trials specifically for overt hypothyroidism, and there are no clinical trials testing ashwagandha in people with overt hypothyroidism. On ashwagandha safety, which the post explicitly denies: there are at least three case reports of people developing thyrotoxicosis, meaning excessively high thyroid hormone levels, from supplementing with ashwagandha. A review reports that gastrointestinal side effects, immune hypersensitivity, liver toxicity, and endocrine disruption have been reported, particularly with prolonged or excessive usage, and the endocrine-modulating activity of ashwagandha has been implicated in thyrotoxicosis and adrenal suppression. Multiple published case reports describe ashwagandha-associated acute liver injury, including a 22-year-old healthy female who suffered moderate to severe liver injury following ingestion of ashwagandha capsules. A hormonal-activity review also notes a case report describing a 73-year-old female who replaced her levothyroxine treatment with the supplement. On selenium: a Cochrane systematic review concluded that selenium supplementation in people with Hashimoto's thyroiditis might reduce antibody levels and result in a decreased dosage of levothyroxine, and may provide other beneficial effects such as on mood and health-related quality of life. This describes possible dose reduction as an adjunct, not replacement, and the review characterized the underlying evidence as limited. On nutrient "depletion": no credible source was found establishing that levothyroxine depletes selenium, zinc, iron, B12, or iodine. The well-documented interaction runs in the opposite direction. Mineral supplements such as calcium, iron, and magnesium should be avoided for at least 4 hours after a levothyroxine dose, because taken at the same time they attach to levothyroxine in the digestive system and stop the body absorbing it correctly. Iron binds to levothyroxine, and taking them together significantly reduces the amount of thyroid hormone absorbed, which can lead to hypothyroid symptoms such as tiredness, weight gain, feeling cold, and dry skin. The only document found asserting levothyroxine-caused depletion was an unsourced nutrient-depletion handout on a chiropractic clinic website, which is tier-8 material and not usable as evidence. On palpitations and bone loss: these are recognized consequences of excess thyroid hormone exposure, that is, overtreatment, rather than effects of correctly dosed replacement. A review of TSH-suppressive therapy frames the issue as needing to consider potential harm of exogenous thyrotoxicosis including atrial fibrillation, osteoporosis, osteopenia, tachycardia, older age, and menopause, and eventually downgrade the TSH target values. A Thyroid review found that greater TSH suppression following thyroidectomy was linked to lower bone mineral density, osteoporosis and increased fracture risk in some studies analyzed. Findings are not uniform: in one cohort, the risk for osteoporotic fracture did not differ between patients and controls.
Complete reasoning
The reply is formatted for pasting into the thread where the claim is circulating.